DOWNLOAD
  • QUIT SMOKING NOW
    Download Clickotine™ application, commit to quit, and enjoy a healthier life!
  • DEVELOPED BY DOCTORS
    Clickotine™ is developed by physicians and clinical neuroscientists at top academic medical centers. We use cutting-edge clinical research to develop evidence-based approaches to help you overcome your cravings and quit smoking now.
  • BASED ON CLINICAL RESEARCH
    Extensive clinical research supports the use of behavioral modification, cognitive modification and controlled deep breathing as potentially effective methods for decreasing signs and symptoms of multiple neuropsychiatric conditions including anxiety and addiction.
  • COMING SOONALZHEIMER’S DISEASE
    Click Therapeutics, Inc. is currently developing a Digital Therapeutic™ application to target symptoms of Alzheimer's disease.
  • COMING SOONTRAUMATIC BRAIN INJURY
    Click Therapeutics, Inc. is currently developing a Digital Therapeutic™ application to target symptoms of Traumatic Brain Injury.
  • COMING SOONATTENTION DEFICIT HYPERACTIVITY DISORDER
    Click Therapeutics, Inc. is currently developing a Digital Therapeutic™ application to target symptoms of Attention Deficit Hyperactivity Disorder.

Click here to Learn More About the Science Behind

Personalized Cognitive-Behavioral Change

Clickotine™ users engage an interactive platform engineered to modulate brain systems underlying motivation and execution.
 

Nicotinic Uncoupling

Clickarettes™ are digital, de-nicotinized cigarettes. Sensorimotor pleasures of smoking are coupled with non-nicotine reinforcers to induce neuroplastic change and promote goal-attainment.
 

Controlled Deep Breathing

Clickotine™ users engage in guided breathing exercises to reduce cravings and anxiety.

Mobile Neuroscience

Clickotine™ provides a brain-based user experience, delivering contextualized interactions based on individual profile and preference. A simplified, actionable heuristic model of cognitive-behavioral change guides the delivery of smoking cessation content.

Two parallel frontal lobe brain systems are critical. The first is a bottom-up, ascending pathway corresponding to motivation. It is activated when users initiate and maintain desired behaviors, experience pleasure, and receive rewards. The second is a top-down, descending frontal lobe pathway corresponding to execution. It is empowered when users formulate goals and strategies, make decisions, and effectively self-regulate.

Both the motivation and execution systems are systematically engaged through multiple interaction modalities, including delivery of text-message tips, cognitive strategies, and personalized feedback. Clickotine™ users also maintain their own profiles reflecting current smoking behavior and motives, quit preferences and barriers. The goal is to promote self-cognition, training individuals to dynamically modulate their own brain and behavior. Users thereby become their own agents of change, and gain the ability to tap into their motivation or execution resources in response to changing circumstances and the challenges of breaking the smoking habit.

 

Dissociating Nicotine and Smoking

A conventional cigarette is a powerful system to deliver rapid, self-titrated doses of nicotine to the human brain. However, psychological and neuroscientific studies have demonstrated convincingly that smoking addiction is sustained by non-nicotinic mechanisms as well. Among these, sensorimotor experiences (mouth, hand, lung, visual, olfactory, etc.) provide significant reinforcement and are coupled with nicotine surges.

Along these lines, de-nicotinized cigarettes are actually effective smoking cessation aids. In fact, craving smokers are not satisfied with rapid infusions of intravenous nicotine, but report that de-nicotinized cigarettes markedly reduce cravings. Clickotine™ repeatedly exposes a smoker to non-nicotinic stimuli to reinforce sensorimotor pleasures of smoking, mitigate cravings, and increase the likelihood of nicotinic uncoupling.

Cue exposure therapies have been implemented in the treatment of addiction disorders for decades. Behavioral interventions aiming to extinguish a conditioned response are well established in clinical practice. All smoking cessation aids, including nicotine replacement and pharmaceuticals, should be complementary to Clickotine™.

 

Hooked on Fresh Air

Breathing is not simply an essential physiological function. The benefits and pleasures of controlled breathing have been realized throughout centuries and civilizations. In more recent decades, peer-reviewed scientific literature has demonstrated that controlled deep breathing can reduce anxiety and other negative psychological states, probably via vagal tone modulation and autonomic self-regulation.

Numerous studies have demonstrated that controlled deep breathing can significantly reduce smoking withdrawal symptoms, including cravings and irritability. Deep breathing is surely one of the most potent non-nicotinic experiences of smoking, and is a critical driver of Clickotine™’s approach to nicotinic uncoupling.

By reproducing sensorimotor aspects of cigarette smoking along with negative-affect reversal, controlled deep breathing is both a pleasurable and a non-nicotinic reinforcer. Clickotine™ use should strengthen mental representations originally encoded via nicotine reinforcement, and promote behaviors which are actually non-toxic and non-lethal!

The science behind Clickotine™ is derived from numerous clinical studies and academic, peer-reviewed publications from diverse disciplines connected to the brain. Integrating decades of prior discoveries into a usable mobile technology would in itself meet a vital unmet need. As a forward-looking, research-driven organization, Click Therapeutics is committed to generating unique data, deploying novel methodology, and demonstrating Clickotine’s™ value in rigorous efficacy trials.